CN100588405C - 去氧氟尿苷粉针剂及其制备方法 - Google Patents
去氧氟尿苷粉针剂及其制备方法 Download PDFInfo
- Publication number
- CN100588405C CN100588405C CN200610096826A CN200610096826A CN100588405C CN 100588405 C CN100588405 C CN 100588405C CN 200610096826 A CN200610096826 A CN 200610096826A CN 200610096826 A CN200610096826 A CN 200610096826A CN 100588405 C CN100588405 C CN 100588405C
- Authority
- CN
- China
- Prior art keywords
- weight
- freeze
- parts
- fine straining
- deoxyuridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002347 injection Methods 0.000 title claims abstract description 43
- 239000007924 injection Substances 0.000 title claims abstract description 43
- 239000000843 powder Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 title claims description 22
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 title claims description 22
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 claims abstract description 55
- 229950005454 doxifluridine Drugs 0.000 claims abstract description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 22
- 229920002307 Dextran Polymers 0.000 claims description 21
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 20
- 229930195725 Mannitol Natural products 0.000 claims description 20
- 239000000594 mannitol Substances 0.000 claims description 20
- 235000010355 mannitol Nutrition 0.000 claims description 20
- 239000012528 membrane Substances 0.000 claims description 19
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 18
- 239000000600 sorbitol Substances 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 238000005303 weighing Methods 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 238000005261 decarburization Methods 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 10
- 239000011521 glass Substances 0.000 claims description 10
- 238000012856 packing Methods 0.000 claims description 10
- 238000004806 packaging method and process Methods 0.000 claims description 9
- 238000009287 sand filtration Methods 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 8
- 239000008215 water for injection Substances 0.000 claims description 7
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 5
- 229910052719 titanium Inorganic materials 0.000 claims description 5
- 239000010936 titanium Substances 0.000 claims description 5
- 238000004042 decolorization Methods 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 238000005262 decarbonization Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 abstract description 21
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract description 12
- 238000010253 intravenous injection Methods 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 description 17
- 239000008174 sterile solution Substances 0.000 description 16
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000002671 adjuvant Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 5
- 238000005286 illumination Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 239000001116 FEMA 4028 Substances 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 4
- 229960004853 betadex Drugs 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 229960002949 fluorouracil Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 240000007711 Peperomia pellucida Species 0.000 description 3
- JVFGXECLSQXABC-UHFFFAOYSA-N ac1l3obq Chemical compound O1C(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(O)C2O)C(COCC(O)C)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC2C(O)C(O)C1OC2COCC(C)O JVFGXECLSQXABC-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 210000003725 endotheliocyte Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical group OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 102000001853 Pyrimidine Phosphorylases Human genes 0.000 description 2
- 108010054917 Pyrimidine Phosphorylases Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
处方1 | 处方2 | 处方3 | 处方4 | 处方5 | 处方6 | 处方7 | 处方8 | |
去氧氟尿苷(g) | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
乳糖(g) | 40 | |||||||
氯化钠(g) | 40 | |||||||
甘氨酸(g) | 40 | |||||||
甘露醇(g) | 40 | |||||||
山梨醇(g) | 40 | |||||||
低分子右旋糖酐(g) | 40 | |||||||
β-环糊精(g) | 40 | |||||||
溶解时限(秒) | 242 | 216 | 207 | 98 | 84 | 91 | 124 | 62 |
1号(%) | 2号(%) | 3号(%) | 4号(%) | 5号(%) | 6号(%) | 7号(%) | 8号(%) | 9号(%) | |
0月 | 99.8 | 99.4 | 99.6 | 99.9 | 99.7 | 99.6 | 100.2 | 99.7 | 99.5 |
1月 | 97.2 | 99.4 | 97.2 | 97.6 | 99.4 | 99.8 | 99.5 | 99.6 | 96.3 |
2月 | 94.4 | 99.2 | 95.6 | 95.7 | 99.1 | 99.2 | 99.5 | 99.2 | 92.8 |
3月 | 92.1 | 98.5 | 93.2 | 92.3 | 98.4 | 98.7 | 98.8 | 99.4 | 89.7 |
6月 | 83.4 | 97.3 | 87.5 | 85.1 | 97.8 | 97.5 | 98.2 | 99.1 | 79.9 |
1号(%) | 2号(%) | 3号(%) | 4号(%) | 5号(%) | 6号(%) | 7号(%) | 8号(%) | 9号(%) | |
0月 | 99.8 | 99.4 | 99.6 | 99.9 | 99.7 | 99.6 | 100.2 | 99.7 | 99.5 |
1月 | 95.4 | 99.2 | 96.4 | 95.7 | 98.7 | 99.1 | 99.2 | 99.8 | 95.2 |
2月 | 91.7 | 98.3 | 93.5 | 91.9 | 98.2 | 98.4 | 98.2 | 99.6 | 89.7 |
3月 | 87.5 | 97.6 | 90.2 | 87.4 | 97.3 | 97.5 | 97.6 | 99.2 | 85.1 |
6月 | 75.4 | 95.8 | 81.3 | 77.1 | 95.7 | 95.3 | 95.9 | 99.1 | 71.2 |
处方9 | 处方10 | 处方11 | 处方12 | 处方13 | 处方14 | |
去氧氟尿苷(g) | 100 | 100 | 100 | 100 | 100 | 100 |
甘露醇(g) | 20 | 20 | 20 | |||
山梨醇(g) | 20 | 20 | 20 | |||
低分子右旋糖酐(g) | 20 | 20 | 20 | |||
β-环糊精(g) | 20 | 20 | 20 | |||
溶解时限(秒) | 88 | 105 | 104 | 70 | 75 | 92 |
处方9(%) | 处方10(%) | 处方11(%) | 处方12(%) | 处方13(%) | 处方14(%) | |
0月 | 99.8 | 99.6 | 99.7 | 99.5 | 99.6 | 99.9 |
1月 | 99.5 | 99.6 | 99.5 | 99.6 | 99.4 | 99.8 |
2月 | 99.1 | 99.0 | 98.8 | 99.4 | 99.2 | 99.5 |
3月 | 98.6 | 98.7 | 98.5 | 99.2 | 99.0 | 99.3 |
6月 | 97.4 | 97.8 | 97.3 | 98.4 | 98.5 | 98.5 |
处方9(%) | 处方10(%) | 处方11(%) | 处方12(%) | 处方13(%) | 处方14(%) | |
0月 | 99.8 | 99.6 | 99.7 | 99.5 | 99.4 | 99.9 |
1月 | 99.2 | 99.1 | 99.2 | 99.4 | 99.2 | 99.5 |
2月 | 98.2 | 98.1 | 98.4 | 99.0 | 98.7 | 99.0 |
3月 | 97.7 | 97.4 | 97.1 | 98.1 | 98.4 | 98.5 |
6月 | 95.2 | 95.1 | 95.4 | 97.2 | 97.0 | 97.1 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610096826A CN100588405C (zh) | 2006-10-19 | 2006-10-19 | 去氧氟尿苷粉针剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610096826A CN100588405C (zh) | 2006-10-19 | 2006-10-19 | 去氧氟尿苷粉针剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1943559A CN1943559A (zh) | 2007-04-11 |
CN100588405C true CN100588405C (zh) | 2010-02-10 |
Family
ID=38043354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200610096826A Active CN100588405C (zh) | 2006-10-19 | 2006-10-19 | 去氧氟尿苷粉针剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100588405C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105343029B (zh) * | 2015-12-08 | 2018-10-12 | 上海朝晖药业有限公司 | 一种去氧氟尿苷胶囊及其制备方法 |
-
2006
- 2006-10-19 CN CN200610096826A patent/CN100588405C/zh active Active
Non-Patent Citations (4)
Title |
---|
高效液相色谱法测定5-氟-2’-脱氧尿嘧啶核苷(氟尿苷)粉针剂的含量. 马张英,屠凌岚,李文钧,彭小英.药物分析杂志,第24卷第5期. 2004 |
高效液相色谱法测定5-氟-2’-脱氧尿嘧啶核苷(氟尿苷)粉针剂的含量. 马张英,屠凌岚,李文钧,彭小英.药物分析杂志,第24卷第5期. 2004 * |
高效液相色谱法测定脱氧氟尿苷粉针和胶囊的含量. 马张英,李文钧,彭小英,裘飞君.药物分析杂志,第24卷第1期. 2004 |
高效液相色谱法测定脱氧氟尿苷粉针和胶囊的含量. 马张英,李文钧,彭小英,裘飞君.药物分析杂志,第24卷第1期. 2004 * |
Also Published As
Publication number | Publication date |
---|---|
CN1943559A (zh) | 2007-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW457095B (en) | Pharmaceutical formulations comprising epothilones and lyophilised compositions comprising epothilones | |
KR101502533B1 (ko) | 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법 | |
CN110917345B (zh) | 一种化疗免疫组合药物及其制备方法 | |
JP4890732B2 (ja) | 癌治療用パクリタキセル・リポソーム組成物およびその製造方法 | |
CN101366696B (zh) | 一种紫杉醇的水溶性注射用药物组合物、制备方法及用途 | |
CN102614491B (zh) | 一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途 | |
CN108853032B (zh) | 一种注射用氟尿嘧啶组合物冻干粉剂 | |
CN100563646C (zh) | 一种奥沙利铂脂质体葡萄糖制剂的制备方法 | |
CN101530393B (zh) | 一种克林霉素磷酸酯脂质体冻干制剂 | |
CN104721131B (zh) | 一种用于肿瘤原位治疗的凝胶制剂及制备方法 | |
CN101961311B (zh) | 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法 | |
Liu et al. | Thermosensitive selenium hydrogel boosts antitumor immune response for hepatocellular carcinoma chemoradiotherapy | |
CN101912361B (zh) | 一种盐酸头孢替安/无水碳酸钠药物组合物混悬注射剂及其新应用 | |
WO2002007708A1 (fr) | Injection de lentinane sous forme de poudre lyophilisee et son procede de preparation | |
CN100588405C (zh) | 去氧氟尿苷粉针剂及其制备方法 | |
CN102342931A (zh) | 替莫唑胺的可注射的胃肠外用药物制剂及其制备方法 | |
CN103845295A (zh) | 一种注射用帕洛诺司琼制剂及其制备方法 | |
CN102210686A (zh) | 一种含更昔洛韦化合物的药物组合物及其制备方法 | |
CN101190214A (zh) | 紫杉醇注射液及其制备方法 | |
CN104940135A (zh) | 一种氟康唑注射液及其制备方法 | |
US11957758B2 (en) | Pharmaceutical composition of docetaxel conjugate and preparation method | |
CN102793678B (zh) | 一种不含吐温的多烯紫杉醇注射剂的制备方法 | |
CN101129374B (zh) | 长春氟宁药物组合物及其制备方法与应用 | |
CN112891557A (zh) | 一种ICG-β-环糊精载药系统及其制备方法和应用 | |
CN101874788A (zh) | 一种7-乙基-10-羟基喜树碱脂质体冻干粉针及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU SHENLONG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HU ZHUANLIANG Effective date: 20110526 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210008 NO. 6, BEIJING WEST ROAD, NANJING CITY, JIANGSU PROVINCE TO: 224200 NO. 18, HEDUO NORTH ROAD, DONGTAI CITY, YANCHENG CITY, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110526 Address after: 224200 Jiangsu Province, Yancheng City Dongtai City Ho duo Road No. 18 Patentee after: Jiangsu Shenlong Pharmaceutical Co., Ltd. Address before: 210008 No. 6 West Beijing Road, Jiangsu, Nanjing Patentee before: Hu Chuanliang |
|
CP01 | Change in the name or title of a patent holder |
Address after: 224200 Jiangsu Province, Yancheng City Dongtai City Ho duo Road No. 18 Patentee after: Jiangsu Shenlong pharmaceutical Limited by Share Ltd Address before: 224200 Jiangsu Province, Yancheng City Dongtai City Ho duo Road No. 18 Patentee before: Jiangsu Shenlong Pharmaceutical Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP03 | Change of name, title or address |
Address after: No.15 Weiba Road, Dongtai City, Yancheng City, Jiangsu Province 224200 Patentee after: JIANGSU SHENLONG PHARMACEUTICAL Co.,Ltd. Address before: 224200, No. 18 North Road, Dongtai, Jiangsu, Yancheng City Patentee before: JIANGSU SHENLONG PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address |